Effectiveness of novel iron regulators in the treatment of diabetic nephropathy

Obrazek miniatury
Banerjee, Dekai
Kaur, Ginpreet
Chatterjee, Bappaditya
Joshi, Hemant
Ramniwas, Seema
Tuli, Hardeep Singh
Tytuł czasopisma
Tytuł tomu
Publishing Office of the University of Rzeszow
Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.
Słowa kluczowe
acute kidney injury , chronic kidney disease , end-stage renal disease , iron chelators , renal iron handling
European Journal of Clinical and Experimental Medicine T. 21, z. 3 (2023), s. 639-647